- Solutions
Our solutions
- OverviewOur workflow solutions give you the data, tools, and insights to power every decision
- Strategic IntelligenceGet a complete view of strategic issues and stay ahead of emerging disruptive themes
- Sales IntelligenceOur workflow solutions give you the data, tools, and insights to power every decision
- Industry
- Platform
Our platform
Your powerful intelligence platform
Explore the fully comprehensive productivity and insights platform
- Company
We are GlobalData
The introduction of a 0.4% Merchant Discount Rate (MDR) on Person-to-Merchant (P2M) Unified Payments Interface (UPI) transactions above INR 2,000 ($20.8) has sparked substantial debate among influencers on X. Influencers see the measure as an attempt to create a durable revenue base for banks, acquirers, and payment platforms, but they also expect merchants to test […]
Physical AI to redefine the future of robotics, says GlobalData
Physical AI marks a shift from machines that follow fixed instructions to embodied systems that perceive, reason, and act autonomously. It can be deployed in robots, autonomous vehicles, drones, and industrial systems. Commercialization began in 2026 across industries ranging from discrete manufacturing and healthcare to mining, energy, and transportation. It will accelerate from 2027 as […]
Slackforce Surfaces strengthens Slackbot’s role as an AI-powered enterprise interface, says GlobalData
Slackforce Surfaces marks a significant advance in AI-enabled enterprise collaboration, turning Slackbot into a practical interface for live business data and context. By automatically creating and refreshing dashboards, reports, presentations, and other views, the capability can reduce the friction of gathering information while helping users derive deeper insights and make faster, more informed decisions, says […]
AI emerges as growing competitive threat to UK commercial brokers, reveals GlobalData
UK commercial brokers are increasingly recognizing artificial intelligence (AI) as a competitive threat, as conversational AI creates new ways for customers to research insurance and obtain pricing without initially engaging a broker, according to a survey by GlobalData, a leading intelligence and productivity platform. GlobalData’s 2026 UK Commercial Broker Survey* found that 9.2% of brokers […]
Fed rate hike points to sustained rate pressure and stronger dollar, says GlobalData
Following the US Federal Reserve’s decision on 16 September 2026 to raise the federal funds rate target range by 25 basis points from 3.75% to 4%; Jaison Davis, Economic Research Analyst at GlobalData, a leading intelligence and productivity platform, provides his perspective: “This is a credibility move. Headline inflation is stuck at 3.4%, well above […]
Classical Hodgkin lymphoma diagnosed incident cases to reach 28,000 across 8MM in 2035, forecasts GlobalData
The burden of diagnosed incident cases of classical Hodgkin lymphoma in the 8MM* is forecast to increase at an annual growth rate (AGR) of 0.31%, from 27,000 in 2025 to 28,000 cases in 2035, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Hodgkin Lymphoma: Epidemiology Report and Forecast,” reveals that the […]
Lunsekimig results bolster Sanofi’s strategy to defend respiratory franchise ahead of Dupixent patent expiry, says GlobalData
Lunsekimig’s Phase IIb asthma data strengthen its case as a differentiated next-generation biologic, with dose-dependent reductions in exacerbations and improvements in lung function supporting progression into Phase III. The results could sharpen Sanofi’s strategy to defend its respiratory franchise ahead of Dupixent’s patent expiry, while intensifying competition in an increasingly crowded asthma biologics market, says […]
Tozorakimab results broaden biologic treatment across COPD population, says GlobalData
Tozorakimab’s (interleukin-33 (IL-33) inhibitor) Phase III chronic obstructive pulmonary disease (COPD) results strengthen the case for a new class of biologic treatment that could extend beyond eosinophil-defined patients. Consistent efficacy across OBERON and TITANIA trials, including those with low eosinophil counts, could broaden the addressable COPD population and intensify competition in a market where current […]
Autoliv’s Toyota onboarding for HBM suite highlights race to industrialize virtual crash testing, says GlobalData
Virtual safety engineering is moving from a research and development (R&D) adjunct to a core pillar of vehicle development as automakers face shorter product cycles, stricter consumer-safety expectations, and rising complexity from electrification and advanced driver-assistance systems (ADAS). Against this backdrop, Autoliv onboarding Toyota as the first customer to assess its Human Body Model (HBM) […]
Vodafone TV will boost VodafoneThree’s UK fixed-mobile multiplay push but needs sharper differentiation, says GlobalData
Vodafone TV’s October 2026 launch will strengthen VodafoneThree’s UK fixed-mobile convergence strategy by filling a key pay-TV gap and extending TV access to mobile-only customers. The move could accelerate multiplay adoption and support 5G+ and broadband cross-selling, but the British telco needs stronger operator-specific benefits and bundled incentives to establish a compelling proposition in an […]
Americas to lead global microgrids market growth through 2030, forecasts GlobalData
The global microgrids market is poised for strong growth as governments, utilities, commercial facilities, military bases, and remote communities increase investment in resilient, decentralized, and digitally managed power systems. Rising grid reliability concerns, extreme weather events, renewable energy integration, and the need for a secure and reliable power supply are accelerating microgrid deployment across critical […]
AstraZeneca’s AZD6793 holds potential to expand oral COPD treatment options, says GlobalData
At the European Respiratory Society (ERS) Congress 2026, AstraZeneca presented the design of the Phase IIb PRESTO trial, a large study set to evaluate whether AZD6793, an oral IRAK4 inhibitor, can reduce disease exacerbations in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). By targeting a shared signalling protein downstream of several […]
Mobileye Drive’s permit share in Germany points to more regulated, fleet-led path for Level 4 autonomy, says GlobalData
The autonomous vehicle (AV) market is increasingly bifurcated: most near-term revenues are coming from advanced driver assistance and limited “supervised” automation in consumer cars, while Level 4 progress is being concentrated in geofenced pilots for shuttles, ride-pooling, and goods movement where regulators can tightly define operating conditions. Against this backdrop, Mobileye Drive’s significant share of […]
Influencers see Apple’s latest iPhone launch as strategic pricing reset to lift premium mix, reveals GlobalData
Apple’s latest product launch during the recent “Surprise and Shine” event sparked strong reactions from influencers on X. While the iPhone Duo’s price drew immediate attention, influencers also pointed to Apple’s simultaneous price increases across older and mainstream iPhone models as evidence that the company is resetting the pricing structure of its wider portfolio. Many […]
PPPs reshape Gulf infrastructure delivery as governments expand private-sector participation, says MEED, a GlobalData company
Dubai, UAE — 11September 2026: Public-private partnerships (PPPs) are becoming an important mechanism for infrastructure delivery across the Middle East and North Africa, with the Gulf Cooperation Council (GCC) leading the shift as governments diversify their economies and expand private-sector participation, reveals MEED, the Middle East-focused business intelligence platform of GlobalData Plc. The growth of […]
Mabwell’s 9MW1911 data support further testing of ST2 blockade in COPD, says GlobalData
At the European Respiratory Society (ERS) Congress 2026, Mabwell and collaborating investigators presented results from the company’s Phase Ib/IIa study in patients with chronic obstructive pulmonary disease (COPD). The randomized, double-blind, placebo-controlled trial evaluated the therapeutic efficacy and safety of 9MW1911, an anti-ST2 monoclonal antibody, in moderate-to-severe COPD. Although the efficacy findings were exploratory and […]
Apple intends to mainstream foldable smartphones using its installed base and brand power, says GlobalData
Following the news that Apple unveiled its first foldable smartphone, the iPhone Duo, amid a flurry of product announcements at its annual September showcase; Amanda Mitchell, Senior Analyst – Telecoms Practice, Technology at GlobalData, a leading intelligence and productivity platform, offers her view: “The move signals Apple’s intent to put its brand gravity and installed base […]
Zorevunersen holds potential to transform Dravet syndrome treatment landscape, says GlobalData
At the 2026 European Epilepsy Congress (EEC), Stoke Therapeutics and partner Biogen unveiled new long-term data from open-label extensions (OLEs) of their phase I/IIa studies of zorevunersen. The four-year OLE results showed substantial and durable seizure reductions, as well as continued improvements in cognition and behavior. The results are pivotal and could mark a shift […]
China’s rise as a biopharma innovation hub reshapes global dealmaking strategies, says GlobalData
China’s biopharma ecosystem is reshaping how global pharmaceutical companies source innovation, build pipelines and structure deals. As Chinese-origin assets gain global validation and licensing values rise, China is becoming an increasingly strategic component of international growth strategies while regulatory and geopolitical complexity raises the stakes for companies deciding how deeply to engage, says GlobalData Healthcare, […]
ERS 2026 data positions Infex’s RESP-X at forefront of Pa-colonized NCFB space, says GlobalData
At the 2026 European Respiratory Society (ERS) International Congress, Infex Therapeutics presented a new analysis of Phase IIa results for RESP-X (INFEX702) in P. aeruginosa (Pa)-colonized non-cystic fibrosis bronchiectasis (NCFB). This matters because, despite the 2025 approval of Insmed’s Brinsupri (brensocatib) as the first therapy for NCFB, no approved treatment yet targets Pa, the disease’s […]